Average Co-Inventor Count = 4.25
ph-index = 4
The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.
Company Filing History:
1. Janssen Biotech, Inc. (14 from 410 patents)
14 patents:
1. 12448455 - Combination therapies with bispecific anti-EGFR/c-met antibodies and third generation EGFR tyrosine kinase inhibitors
2. 12304939 - EGFR and C-met fibronectin type III domain binding molecules
3. 12247077 - Bispecific EGFR/c-Met antibodies
4. 12215161 - Combination therapies and patient stratification with bispecific anti-EGFR/c-Met antibodies
5. 12215160 - Treatment of patients having c-met exon 14 skipping mutations
6. 11879013 - Combination therapies with bispecific anti-EGFR/c-Met antibodies and third generation EGFR tyrosine kinase inhibitors
7. 11459391 - Combination therapies and patient stratification with bispecific anti-EGFR/c-Met antibodies
8. 10954284 - EGFR and c-Met fibronectin type III domain binding molecules
9. 10662235 - Cysteine engineered fibronectin type III domain binding molecules
10. 9725497 - EGFR and C-Met fibronectin type III domain binding molecules
11. 9695242 - Bispecific EGFR/c-Met antibodies
12. 9695228 - EGFR and c-Met fibronectin type III domain binding molecules
13. 9593164 - Bispecific EGFR/c-Met antibodies
14. 9580508 - Bispecific EGFR/c-Met antibodies